PeptImmune land $8.2M in series D

Cambridge, MA-based PeptImmune has garnered $8.2 million in a fourth round of funding. New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital led the round. The funding will be used to advance clinical development of Peptimmune's multiple sclerosis treatment, PI-2301. Additional funding, and a new, unnamed investor, are expected in the second quarter of 2008.

"The Series D investment will provide the necessary capital to complete two clinical trials by the end of 2008...The completion of these two studies will offer proof of principal for PI-2301, which is a second generation copolymer targeted at treating patients with relapsing and remitting multiple sclerosis," noted PeptImmune's CEO Thomas P. Mathers.

- see PeptImmune's release
- read this Mass High Tech report for more

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.